Read by QxMD icon Read

early hepatocellular carcinoma

Fabio Piscaglia, Sadahisa Ogasawara
Background: Liver cancer is the second most common cause of cancer-related death, with hepatocellular carcinoma (HCC) accounting for most primary liver cancers and most commonly arising from a history of advanced chronic liver disease. Among the available therapies, transarterial chemoembolization (TACE) is the most widely utilized and is considered the first-line treatment recommended for patients staged as intermediate HCC (Barcelona Clinic Liver Cancer stage B). If applied correctly, TACE can produce survival benefits without adversely affecting hepatic functional reserve...
March 2018: Liver Cancer
Tom Tan-To Cheung, Philip Chong-Hei Kwok, Stephen Chan, Chin-Cheung Cheung, Ann-Shing Lee, Victor Lee, Hoi-Ching Cheng, Nam-Hung Chia, Charing C N Chong, Tak-Wing Lai, Ada L Y Law, Mai-Yee Luk, Chi Chung Tong, Thomas C C Yau
Background: Hepatocellular carcinoma (HCC) is highly prevalent in Hong Kong due to the high prevalence of chronic hepatitis B infection. Liver cancer is the fourth most common cancer and the third most common cause of cancer death. Due to the high case load, there is a high level of local expertise in treating HCC, and the full spectrum of treatment modalities is available. This document summarizes how these modalities should be used based on the latest evidence. Summary: In 2 meetings held in early 2017, a multidisciplinary group of Hong Kong clinicians, including liver surgeons, interventional radiologists, clinical oncologists, and medical oncologists, met to update local consensus statements for management of HCC...
March 2018: Liver Cancer
Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Hee Yeon Kim, Chang Wook Kim, Chan Ran You, Sang Wook Choi, Se Hyun Cho, Joon-Yeol Han, Do Seon Song, U Im Chang, Jin Mo Yang, Hae Lim Lee, Sung Won Lee, Nam Ik Han, Seok-Hwan Kim, Myeong Jun Song, Seawon Hwang, Pil Soo Sung, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
Patients with chronic hepatitis C who achieve a sustained viral response after pegylated interferon therapy have a reduced risk of hepatocellular carcinoma, but the risk after treatment with direct-acting antivirals is unclear. We compared the rates of early development of hepatocellular carcinoma after direct-acting antivirals and after pegylated interferon therapy. We retrospectively analyzed 785 patients with chronic hepatitis C who had no history of hepatocellular carcinoma (211 treated with pegylated interferon, 574 with direct-acting antivirals) and were followed up for at least 24 weeks after antiviral treatment...
April 16, 2018: Journal of Viral Hepatitis
Toshie Mashiba, Kouji Joko, Masayuki Kurosaki, Hironori Ochi, Yukio Osaki, Yuji Kojima, Ryo Nakata, Tohru Goto, Akahane Takehiro, Hiroyuki Kimura, Akeri Mitsuda, Chiharu Kawanami, Yasushi Uchida, Chikara Ogawa, Atsunori Kusakabe, Ryuichi Narita, Yasushi Ide, Takehiko Abe, Keiji Tsuji, Tadashi Kitamura, Kazuhiko Okada, Tetsuro Sohda, Masaya Shigeno, Takashi Satou, Namiki Izumi
BACKGROUND AND AIM: This study aimed to elucidate whether interferon (IFN)-free direct-acting antiviral (DAA) therapy for hepatitis C after curative treatment of hepatocellular carcinoma (HCC) promotes HCC recurrence in a real-world large-scale cohort. METHODS: This multicenter study was conducted by the Japanese Red Cross Hospital Liver Study Group. This retrospective study analyzed 516 patients who underwent antiviral treatment for hepatitis C with either IFN (n = 148) or IFN-free DAA (n = 368) after curative HCC treatment; 78 IFN-treated patients and 347 IFN-free DAA-treated patients achieved sustained virological response (SVR)...
2018: PloS One
Juan Pekolj, Fernando A Alvarez, David Biagiola, Lucas Villegas, Victoria Ardiles, Eduardo de Santibañes
BACKGROUND: The initial mortality rates of associating liver partition and portal vein occlusion for staged hepatectomy (ALPPS) were high. However, recent data from the International Registry show a continuous reduction of early mortality and major morbidity due to risk adjustment in patient selection and less invasive techniques in stage-1 surgery. During the first ALPPS International Consensus in 2015, we introduced a paradigm inversion of ALPPS, the so-called "Mini-ALPPS." METHODS: We combined a partial liver partition with a novel technique of laparoscopic-assisted percutaneous cannulation of the inferior mesenteric vein for intraoperative transmesenteric portal vein embolization...
April 16, 2018: Journal of Laparoendoscopic & Advanced Surgical Techniques. Part A
Grzegorz Boryczka, Marek Hartleb, Małgorzata Janik
Introduction: Diagnosis of hepatocellular carcinoma (HCC) is considerably delayed, being frequently done in the non-curative stage of disease. The reason for delayed diagnosis is indolent course in early stages and/or unspecific symptoms indistinguishable from underlying cirrhosis. Hitherto methods used for screening of HCC have important limitations. TRIMprob is a non-invasive method, which showed utility in detection of cancers located in prostate, breast, or urinary bladder. Aim: To determine the diagnostic accuracy of TRIMprob in detecting HCC in cirrhotic liver...
2018: Przegla̜d Gastroenterologiczny
Shuangshuang Li, Jiping Yao, Mingjie Xie, Yanning Liu, Min Zheng
Hepatocellular carcinoma remains the sixth most lethal malignancy in the world. While HCC is often diagnosed via current biomarkers at a late stage, early detection of HCC has proven to be very difficult. Recent studies have focused on using exosomal miRNAs in clinical diagnostics and therapeutics, because they have improved stability in exosomes than as free miRNAs themselves. Exosomal miRNAs act through novel mechanisms for inducing cellular responses in a variety of biological circumstances. Dysregulated expression of miRNAs in exosomes can also accelerate HCC progression, including cell proliferation and metastasis, via alteration of a network of genes...
April 11, 2018: Journal of Hematology & Oncology
Yaojun Zhang, Junting Huang, Jinbin Chen, Keli Yang, Jiancong Chen, Li Xu, Zhongguo Zhou, Minshan Chen
Background: Although hepatitis B virus (HBV) is still one of the most common etiological factors for hepatocellular carcinoma (HCC), the association between the HBV mutations and the clinical characteristics and prognosis of HBV-related HCC patients (HBV-HCC) after surgical resection remains largely unknown. Materials and methods: A cohort of 131 consecutive patients who received hepatectomy for HBV-HCC were retrospectively enrolled. The HBV genotype and 14 genomic mutations, which have been reported to relate to HCC in liver samples, were sequenced...
2018: Cancer Management and Research
Xiao-Lu Ma, Mi Jiang, Ying Zhao, Bei-Li Wang, Min-Na Shen, Yan Zhou, Chun-Yan Zhang, Yun-Fan Sun, Jian-Wen Chen, Bo Hu, Zi-Jun Gong, Xin Zhang, Ya Cao, Bai-Shen Pan, Jian Zhou, Jia Fan, Xin-Rong Yang, Wei Guo
PURPOSE: Annexin A3 (ANXA3) could induce progression of hepatocellular carcinoma (HCC) via promoting stem cell traits of CD133-positive cells. Moreover, serum ANXA3 showed preliminary diagnostic potential, however further validation was required. Meanwhile, the prognostic value of ANXA3 remained elusive. The present study aimed to validate diagnostic performance and further systematically investigate the prognostic value of serum ANXA3. METHODS: Serum ANXA3 of 368 HCC patients was determined by enzyme-linked immunosorbent assay (ELISA); 295 of these patients underwent resection and 73 underwent transcatheter arterial chemoembolization (TACE)...
April 6, 2018: Annals of Surgical Oncology
Jing Li, Younghee Lee, Yanjian Li, Yu Jiang, Huiping Lu, Wenjuan Zang, Xiaohong Zhao, Liguo Liu, Yang Chen, Haidong Tan, Zhiying Yang, Michael Q Zhang, Tak W Mak, Ling Ni, Chen Dong
The molecular mechanisms whereby CD8+ T cells become "exhausted" in the tumor microenvironment remain unclear. Programmed death ligand-1 (PD-L1) is upregulated on tumor cells and PD-1-PD-L1 blockade has significant efficacy in human tumors; however, most patients do not respond, suggesting additional mechanisms underlying T cell exhaustion. B7 superfamily member 1 (B7S1), also called B7-H4, B7x, or VTCN1, negatively regulates T cell activation. Here we show increased B7S1 expression on myeloid cells from human hepatocellular carcinoma correlated with CD8+ T cell dysfunction...
March 29, 2018: Immunity
Colin M Court, Shuang Hou, Paul Winograd, Nicholas H Segel, Qingyu Wilda Li, Yazhen Zhu, Saeed Sadeghi, Richard S Finn, Ekambaram Ganapathy, Min Song, Samuel W French, Bita V Naini, Shonan Sho, Fady M Kaldas, Ronald W Busuttil, James S Tomlinson, Hsian-Rong Tseng, Vatche G Agopian
Current clinicopathologic staging systems and serum biomarkers poorly discriminate tumor biology in hepatocellular carcinoma (HCC), with high recurrence rates following curative-intent surgical resection and liver transplantation (LT). Identification of accurate biomarkers for improved prognostication and treatment selection is a critical unmet need. We sought to develop a novel "liquid-biopsy" assay capable of detecting HCC circulating tumor cells (CTCs), and characterizing phenotypic subpopulations with prognostic significance...
April 6, 2018: Liver Transplantation
Ahmed M Tahon, Magdy Z El-Ghanam, Samy Zaky, Tarek Mostafa Emran, Ali M Bersy, Fathiya El-Raey, Elsayed A Z, Amr M El Kharsawy, Dina Johar
BACKGROUND: Egypt has high incidence of hepatocellular carcinoma (HCC). This is due to wide spread of hepatitis C virus (HCV) infection which is responsible for most of the cases of liver cirrhosis. The major diagnostic techniques for HCC include serum markers and various imaging modalities. Glypican 3 (GPC3) protein is highly expressed in HCC, but not in normal liver tissue. The significance of GPC3 as a predictor or diagnostic tool for human tumors other than HCC is unclear. AIM: To quantitatively assess the role of GPC3 in diagnosis of HCC in comparison to α-fetoprotein (AFP), ultrasonography (US), and computerized tomography (CT)...
April 6, 2018: Journal of Gastrointestinal Cancer
Annalisa Boscolo, Eugenia Menin, Beatrice Zelaschi, Laura Albertoni, Giacomo Zanus, Fabio Baratto
Graft-versus-host-disease after orthotopic liver transplant is a rare and life-threatening complication. The diagnosis is challenging and usually confirmed by chimerism and skin biopsies. The most common cause of death is sepsis (60%), and broad-spectrum antibiotics and antifungal prophylaxis are strongly recommended. We present a case of a 61-year-old man with hepatocellular carcinoma and a previous history of metabolic and alcoholic cirrhosis who underwent orthotopic liver transplant. The immunosuppression regimen consisted of corticosteroids, calcineurin inhibitor, and mammalian target of rapamycin complex 1 inhibitor...
April 4, 2018: Experimental and Clinical Transplantation
Tatsuo Kanda, Shunichi Matsuoka, Mitsuhiko Moriyama
No abstract text is available yet for this article.
April 4, 2018: Hepatology International
H Y Kim, J Y Nam, J-H Lee, H A Lee, Y Chang, H Y Lee, H Cho, D H Lee, Y Y Cho, E J Cho, S J Yu, J M Lee, Y J Kim, J-H Yoon
BACKGROUND: Data are insufficient regarding the survival benefit of surveillance for hepatocellular carcinoma (HCC). AIMS: To investigate the effectiveness of HCC surveillance in a hepatitis B-endemic population. METHODS: This retrospective cohort study included 1402 consecutive patients who were newly diagnosed with HCC between 2005 and 2012 at a single tertiary hospital in Korea. The primary endpoint was overall survival. Lead-time and length-time biases were adjusted (sojourn time = 140 days) and sensitivity analyses were performed...
April 2, 2018: Alimentary Pharmacology & Therapeutics
Masaki Kaibori, Kengo Yoshii, Kiyoshi Hasegawa, Asao Ogawa, Shoji Kubo, Ryosuke Tateishi, Namiki Izumi, Masumi Kadoya, Masatoshi Kudo, Takashi Kumada, Michiie Sakamoto, Osamu Nakashima, Yutaka Matsuyama, Tadatoshi Takayama, Norihiro Kokudo
OBJECTIVE: We reviewed nationwide follow-up data to determine outcomes of different treatments for early-stage hepatocellular carcinoma (HCC) in elderly patients. SUMMARY BACKGROUND DATA: Outcomes of early-stage HCC treatments in elderly patients have not been prospectively compared. METHODS: We included 6490 HCC patients, aged ≥75 years at treatment, who underwent curative hepatic resection (HR, n = 2020), radiofrequency ablation (RFA, n = 1888), microwave ablation (MWA, n = 193), or transcatheter arterial chemoembolization (TACE, n = 2389), and compared their characteristics and survival...
March 30, 2018: Annals of Surgery
Kylie S Carville, Jennifer MacLachlan, Vicky Thursfield, Benjamin Cowie
BACKGROUND: Liver cancer continues to be a health priority in Australia, with the majority attributable to preventable causes, and certain populations at higher risk. AIMS: Epidemiological assessment of incidence, trends, and distribution to inform prevention, and reassessment of data in light of recent changes to registry case definitions. METHODS: Reported cases of hepatocellular carcinoma in Victoria, Australia, 1984-2013 were obtained from the Victorian Cancer Registry...
March 31, 2018: Internal Medicine Journal
Suzanne Sheppard-Law, Iryna Zablotska-Manos, Melissa Kermeen, Susan Holdaway, Alice Lee, Jacob George, Amany Zekry, Lisa Maher
AIMS AND OBJECTIVES: This study aimed to investigate HCC screening utilisation and factors associated with utilisation among patients prescribed HBV anti-viral therapy and at risk of HCC. BACKGROUND: The incidence of hepatocellular carcinoma (HCC) has increased in Australia over the past three decades with chronic hepatitis B virus (HBV) infection a major contributor. HCC surveillance programs aim to detect cancers early enabling curative treatment options, longer survival and longer times to recurrence...
March 31, 2018: Journal of Clinical Nursing
Zhanliang Su, Xifu Wang, Linfeng Zheng, Tianchu Lyu, Matteo Figini, Bin Wang, Daniel Procissi, Junjie Shangguan, Chong Sun, Liang Pan, Lei Qin, Bin Zhang, Yury Velichko, Riad Salem, Vahid Yaghmai, Andrew C Larson, Zhuoli Zhang
While natural killer (NK) cell-based adoptive transfer immunotherapy (ATI) provides only modest clinical success in cancer patients. This study was hypothesized that MRI-guided transcatheter intra-hepatic arterial (IHA) infusion permits local delivery to liver tumors to improve outcomes during NK-based ATI in a rat model of hepatocellular carcinoma (HCC). Mouse NK cells were labeled with clinically applicable iron nanocomplexes. Twenty rat HCC models were assigned to three groups: transcatheter IHA saline infusion as the control group, transcatheter IHA NK infusion group, and intravenous (IV) NK infusion group...
March 30, 2018: Cancer Medicine
Fengdan Ye, Dongya Jia, Mingyang Lu, Herbert Levine, Michael W Deem
Abnormal metabolism is an emerging hallmark of cancer. Cancer cells utilize both aerobic glycolysis and oxidative phosphorylation (OXPHOS) for energy production and biomass synthesis. Understanding the metabolic reprogramming in cancer can help design therapies to target metabolism and thereby to improve prognosis. We have previously argued that more malignant tumors are usually characterized by a more modular expression pattern of cancer-associated genes. In this work, we analyzed the expression patterns of metabolism genes in terms of modularity for 371 hepatocellular carcinoma (HCC) samples from the Cancer Genome Atlas (TCGA)...
March 13, 2018: Oncotarget
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"